When a single chronic disease rarely arrives alone, clinical management becomes exponentially more complex — and for the tens of millions of older adults navigating diabetes alongside additional diagnoses, this complexity may be defining their care quality and long-term outcomes. Understanding the scale and structure of this overlap is increasingly essential for anyone tracking longevity and metabolic health.
Published in JAMA, this analysis draws attention to the convergence of diabetes and multimorbidity at a population level that demands urgent reconsideration of how metabolic disease is managed. Approximately 40 million Americans currently have diabetes, while another 115 million have prediabetes — a preclinical state often underestimated in its clinical consequences. Particularly striking is the concentration of risk in older populations: more than 30 million adults with prediabetes are aged 65 or older, and over half of this group (52.1%) face a compounded risk profile involving multiple concurrent conditions. Globally, the International Diabetes Federation places current diabetes prevalence above 500 million adults, with projections approaching 900 million by 2050. When prediabetes is folded in, the figure nears 1 billion people today.
The significance of multimorbidity in this context extends well beyond administrative burden. Patients managing diabetes alongside cardiovascular disease, chronic kidney disease, or cognitive decline face drug-drug interactions, conflicting treatment targets, and clinical guidelines that were largely designed for single-disease populations. This analytical piece arrives at a moment when endocrinology and geriatric medicine are only beginning to develop coordinated frameworks. The concern is not only epidemiological scale but clinical coherence: most randomized trials that established standard-of-care diabetes protocols systematically excluded patients with significant comorbidities — precisely the patients now constituting the majority of real-world diabetes cases. This piece is best understood as a call to recalibrate both research priorities and clinical infrastructure, representing a confirmatory and consolidating contribution rather than a novel discovery.